Lyophilisation Conference 2019

SMi Group3 - 4 June 2019, London, UK
SMi Group announces the return of the 7th Annual Lyophilisation Conference. Lyophilisation (or freeze drying) remains one of the most exciting and rapidly advancing technologies in the pharmaceutical industry to date. By 2020, the lyophilisation equipment market is projected to exceed 8% CAGR reaching approximately £4.4 billion.

Attend this conference along with key opinion leaders from all areas of pharmaceuticals and biologicals to explore formulation science, materials characterisation, novel and alternative technologies, mathematical modelling and regulatory updates.

How Will You Benefit?

Network and learn from leading professionals such as:

Chairs for 2019

  • Sune Klint Andersen, Principal Spray Drying,Janssen Pharmaceuticals
  • Xiaodong Chen, Senior Research Investigator,Bristol-Myers Squibb

Key Speakers include

  • Paul Matejtschuk, Principal Scientist & Section Head, Standardisation Science, NIBSC
  • Davide Fissore, Associate Professor, Politecnico di Torino
  • Michael Dekner, Head Fill & Finish LCM support, Takeda
  • Richard Denk, Head Sales Containment, Skan AG
  • Mostafa Nakach, Head of Pharmaceutical Engineering Group, Sanofi-Aventis R&D
  • Daryl Williams, Professor of Particle Science and Director of Discovery space, Imperial College London
  • Kevin Ward, Director of R&D, Biopharma technology
  • Paul Barry, Development Scientist, Genzyme Ireland Ltd/Sanofi

2019 Highlights

  • Explore the recent advances in lyophilisation methods and technologies from Biopharma Technology
  • Discuss the novel methods that characterise complex pharmaceutical products to aid formulation design from NIBSC
  • Gain insight into the approaches to avoid cross contamination during lyophilisation from SKAN AG
  • Discover a new approach towards process design through the use of micro freeze dryers by Politecno di Torino
  • Examine the use of model-based approach to lyophilisation cycle design from Takeda

For further information and to register, please visit:
http://www.lyophilisation-europe.com/wpnwe

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

COVID-19 Long-Acting AntiBody (LAAB) combination A…

AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside th...

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Johnson & Johnson initiates pivotal global Pha…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, J...

Regeneron's REGN-COV2 antibody cocktail reduced vi…

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cockta...

Gilead Sciences signs joint procurement agreement …

Gilead Sciences (Nasdaq: GILD) and the European Commission signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir)...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

Popular COVID-19 conspiracies linked to vaccine 'h…

A new study of beliefs and attitudes toward COVID-19 in five different countries - UK, US, Ireland, Mexico and Spain - has identified how much traction some prominent con...

Scientists identify common vulnerabilities across …

In a study published online in Science, an international team of almost 200 researchers from 14 leading institutions in six countries, including France with the Institut ...

Sanofi and Translate Bio mRNA COVID-19 vaccine can…

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced...

Potential COVID-19 vaccines not affected by domina…

Vaccines currently being developed for COVID-19 should not be affected by recent mutations in the virus, according to a new study involving a University of York virologis...